vs
Side-by-side financial comparison of Ponce Financial Group, Inc. (PDLB) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Ponce Financial Group, Inc. is the larger business by last-quarter revenue ($31.4M vs $20.4M, roughly 1.5× Sight Sciences, Inc.). Ponce Financial Group, Inc. runs the higher net margin — 36.3% vs -20.4%, a 56.7% gap on every dollar of revenue. On growth, Ponce Financial Group, Inc. posted the faster year-over-year revenue change (37.6% vs 6.9%). Ponce Financial Group, Inc. produced more free cash flow last quarter ($54.6M vs $-2.0M). Over the past eight quarters, Ponce Financial Group, Inc.'s revenue compounded faster (23.7% CAGR vs 2.9%).
Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
PDLB vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.4M | $20.4M |
| Net Profit | $10.1M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | 43.6% | -18.0% |
| Net Margin | 36.3% | -20.4% |
| Revenue YoY | 37.6% | 6.9% |
| Net Profit YoY | 245.6% | 64.9% |
| EPS (diluted) | $0.43 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $31.4M | $20.4M | ||
| Q3 25 | $26.7M | $19.9M | ||
| Q2 25 | $26.5M | $19.6M | ||
| Q1 25 | $24.6M | $17.5M | ||
| Q4 24 | $22.8M | $19.1M | ||
| Q3 24 | $20.2M | $20.2M | ||
| Q2 24 | $20.2M | $21.4M | ||
| Q1 24 | $20.5M | $19.3M |
| Q4 25 | $10.1M | $-4.2M | ||
| Q3 25 | $6.5M | $-8.2M | ||
| Q2 25 | $6.1M | $-11.9M | ||
| Q1 25 | $6.0M | $-14.2M | ||
| Q4 24 | $2.9M | $-11.8M | ||
| Q3 24 | $2.4M | $-11.1M | ||
| Q2 24 | $3.2M | $-12.3M | ||
| Q1 24 | $2.4M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | 43.6% | -18.0% | ||
| Q3 25 | 32.8% | -39.7% | ||
| Q2 25 | 30.2% | -59.6% | ||
| Q1 25 | 32.5% | -79.2% | ||
| Q4 24 | 19.6% | -62.5% | ||
| Q3 24 | 15.2% | -55.7% | ||
| Q2 24 | 21.8% | -59.2% | ||
| Q1 24 | 18.3% | -76.4% |
| Q4 25 | 36.3% | -20.4% | ||
| Q3 25 | 24.3% | -41.0% | ||
| Q2 25 | 23.0% | -61.0% | ||
| Q1 25 | 24.2% | -80.8% | ||
| Q4 24 | 14.1% | -62.1% | ||
| Q3 24 | 12.1% | -54.9% | ||
| Q2 24 | 15.8% | -57.7% | ||
| Q1 24 | 11.8% | -84.4% |
| Q4 25 | $0.43 | $-0.07 | ||
| Q3 25 | $0.27 | $-0.16 | ||
| Q2 25 | $0.25 | $-0.23 | ||
| Q1 25 | $0.25 | $-0.28 | ||
| Q4 24 | $0.11 | $-0.23 | ||
| Q3 24 | $0.10 | $-0.22 | ||
| Q2 24 | $0.14 | $-0.25 | ||
| Q1 24 | $0.11 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $126.2M | $92.0M |
| Total DebtLower is stronger | $596.1M | $42.4M |
| Stockholders' EquityBook value | $541.5M | $63.9M |
| Total Assets | $3.2B | $115.3M |
| Debt / EquityLower = less leverage | 1.10× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $126.2M | $92.0M | ||
| Q3 25 | $146.6M | $92.4M | ||
| Q2 25 | $126.6M | $101.5M | ||
| Q1 25 | $129.9M | $108.8M | ||
| Q4 24 | $139.8M | $120.4M | ||
| Q3 24 | $155.8M | $118.6M | ||
| Q2 24 | $103.2M | $118.2M | ||
| Q1 24 | $134.7M | $127.3M |
| Q4 25 | $596.1M | $42.4M | ||
| Q3 25 | $521.1M | $42.4M | ||
| Q2 25 | $536.1M | $42.4M | ||
| Q1 25 | $521.1M | $42.4M | ||
| Q4 24 | $596.1M | $40.0M | ||
| Q3 24 | $580.4M | $37.1M | ||
| Q2 24 | $680.4M | $35.0M | ||
| Q1 24 | $680.4M | $35.0M |
| Q4 25 | $541.5M | $63.9M | ||
| Q3 25 | $529.8M | $64.3M | ||
| Q2 25 | $521.1M | $70.0M | ||
| Q1 25 | $513.9M | $77.6M | ||
| Q4 24 | $505.5M | $87.5M | ||
| Q3 24 | $504.6M | $95.0M | ||
| Q2 24 | $497.7M | $101.6M | ||
| Q1 24 | $493.7M | $109.2M |
| Q4 25 | $3.2B | $115.3M | ||
| Q3 25 | $3.2B | $116.3M | ||
| Q2 25 | $3.2B | $122.0M | ||
| Q1 25 | $3.1B | $129.7M | ||
| Q4 24 | $3.0B | $142.8M | ||
| Q3 24 | $3.0B | $143.6M | ||
| Q2 24 | $2.8B | $149.7M | ||
| Q1 24 | $2.8B | $155.6M |
| Q4 25 | 1.10× | 0.66× | ||
| Q3 25 | 0.98× | 0.66× | ||
| Q2 25 | 1.03× | 0.61× | ||
| Q1 25 | 1.01× | 0.55× | ||
| Q4 24 | 1.18× | 0.46× | ||
| Q3 24 | 1.15× | 0.39× | ||
| Q2 24 | 1.37× | 0.34× | ||
| Q1 24 | 1.38× | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $55.6M | $-1.8M |
| Free Cash FlowOCF − Capex | $54.6M | $-2.0M |
| FCF MarginFCF / Revenue | 173.9% | -9.7% |
| Capex IntensityCapex / Revenue | 3.1% | 0.8% |
| Cash ConversionOCF / Net Profit | 5.48× | — |
| TTM Free Cash FlowTrailing 4 quarters | $74.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $55.6M | $-1.8M | ||
| Q3 25 | $1.4M | $-8.7M | ||
| Q2 25 | $6.2M | $-7.5M | ||
| Q1 25 | $13.1M | $-11.6M | ||
| Q4 24 | $7.2M | $-3.5M | ||
| Q3 24 | $-14.6M | $362.0K | ||
| Q2 24 | $-2.6M | $-9.5M | ||
| Q1 24 | $1.5M | $-9.8M |
| Q4 25 | $54.6M | $-2.0M | ||
| Q3 25 | $786.0K | $-8.9M | ||
| Q2 25 | $5.9M | $-7.8M | ||
| Q1 25 | $12.9M | — | ||
| Q4 24 | $4.5M | $-3.6M | ||
| Q3 24 | $-15.0M | $311.0K | ||
| Q2 24 | $-2.6M | $-9.5M | ||
| Q1 24 | $-315.0K | $-9.9M |
| Q4 25 | 173.9% | -9.7% | ||
| Q3 25 | 2.9% | -44.7% | ||
| Q2 25 | 22.4% | -39.6% | ||
| Q1 25 | 52.6% | — | ||
| Q4 24 | 19.7% | -18.9% | ||
| Q3 24 | -74.1% | 1.5% | ||
| Q2 24 | -13.0% | -44.7% | ||
| Q1 24 | -1.5% | -51.4% |
| Q4 25 | 3.1% | 0.8% | ||
| Q3 25 | 2.3% | 0.9% | ||
| Q2 25 | 1.0% | 1.1% | ||
| Q1 25 | 0.6% | 0.0% | ||
| Q4 24 | 11.9% | 0.7% | ||
| Q3 24 | 2.0% | 0.3% | ||
| Q2 24 | 0.3% | 0.4% | ||
| Q1 24 | 8.7% | 0.6% |
| Q4 25 | 5.48× | — | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 2.20× | — | ||
| Q4 24 | 2.46× | — | ||
| Q3 24 | -5.99× | — | ||
| Q2 24 | -0.80× | — | ||
| Q1 24 | 0.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PDLB
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
